Effects of Omega-3 Supplementation in Sarcopenia After Bariatric Surgery: A Triple-Blind Randomized Controlled Clinical Trial.

Denna trippelblinda randomiserade studie omfattade 58 personer som genomgick bariatrisk kirurgi, varav 81 % var kvinnor, med medelåldern 38,2 år och ett genomsnittligt kroppsmasseindex på 41,1 kg/m². Deltagarna fick 2 000 mg/dag EPA plus DHA eller solrosoljeplacebo i 90 dagar: 15 dagar före operationen och 75 dagar efteråt. Researchers assessed bioelectrical-impedance muscle mass, handgrip strength, and timed up-and-go at baseline, day 45, and day 105 from supplementation start. The groups were similar at baseline in weight, muscle mass, grip strength, and timed up-and-go. Muscle mass fell significantly in both groups between baseline and day 105, by 3.1±0.3 kg in one group and 2.2±0.5 kg in the other. The abstract concludes that omega-3 did not prevent muscle loss or improve strength or functional performance during this early postoperative period. It was safe and well tolerated. This is a useful negative result in a clinically specific setting. It does not test normal aging-related sarcopenia, and bioelectrical impedance is a body-composition measurement rather than a direct clinical outcome. The short perioperative window also leaves longer-term effects unanswered.

Perioperative omega-3 supplementation did not prevent muscle mass loss or improve strength or functional performance within 105 days.